Cerus Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 24% product revenue growth, driven by strong platelet and IFC demand, with raised full-year guidance and continued margin discipline. Innovation and new contracts in the U.S. and EMEA support long-term growth, despite inflation and regulatory uncertainties.
-
INTERCEPT Blood System continues to expand its global leadership in transfusion safety, leveraging strong U.S. and international growth, a robust product pipeline, and strategic partnerships like the BCA agreement. Double-digit revenue growth is expected through 2026, with new product launches and geographic expansion driving future gains.
Fiscal Year 2025
-
Record 2025 revenue and product growth were driven by strong U.S. and EMEA performance, successful INT200 launch, and expanding IFC adoption. 2026 guidance projects continued revenue and EBITDA growth, with BCA agreement and international expansion as key drivers.
-
Record Q3 revenue grew 15% year-over-year, driven by strong platelet and IFC sales. Full-year guidance was raised, margins faced some headwinds, and the shift to IFC kit sales is expected to further improve profitability. Positive outlook continues into 2026.
-
INTERCEPT Blood Systems is expanding globally, with strong financial growth, increased guidance, and new product launches like IFC. Regulatory progress continues for red blood cells, while operational efficiencies and government funding support future expansion.
-
Record Q2 revenue and strong IFC demand led to raised 2025 guidance and fifth straight positive adjusted EBITDA quarter. Growth was broad-based across geographies and products, with new launches and regulatory progress supporting future expansion.
-
INTERCEPT technology is the global standard for platelet safety, driving recurring revenue and market leadership. New product innovations and expanding clinical data support strong financial growth, with major opportunities in red cells and fibrinogen complex ahead.
-
Double-digit revenue growth in Q1 2025 was driven by strong North American platelet and IFC sales, early INT200 device approval, and robust international engagement. Gross margin improved to 58.8%, and positive adjusted EBITDA was achieved for the fourth consecutive quarter.
-
2025 sales are guided at $194–$200 million, with stable margins and durable EBITDA. U.S. platelet share is strong, international expansion is accelerating, and new products like IFC and RBC offer significant long-term growth potential.
Fiscal Year 2024
-
Achieved 15% product revenue growth in 2024, positive adjusted EBITDA, and strong cash flow. Outlook for 2025 includes 8-11% revenue growth, continued margin strength, and expansion in key markets like IFC, China, and Brazil.
-
Transfusion medicine is seeing steady global growth, with INTERCEPT technology expanding in over 40 countries and strong U.S. platelet market momentum. International opportunities in EMEA, LATAM, and China are advancing, while new products like IFC and the LED illuminator support future growth and profitability.
-
Q3 2024 saw strong revenue growth, margin expansion, and positive adjusted EBITDA, driven by U.S. platelet and IFC business momentum. Full-year guidance was raised, and new regulatory and BARDA milestones support future growth.
-
CE Mark review for INTERCEPT RBCs in Europe ended without approval due to impurity data concerns, but new US phase III RECIPE trial results were positive, supporting non-inferiority and safety. A new $248M BARDA contract will fund US regulatory and clinical efforts.
-
Q2 2024 delivered 16% year-over-year product revenue growth, driven by U.S. platelet sales and international expansion, with raised full-year guidance to $175M-$178M. Positive adjusted EBITDA and operating cash flow were achieved, and strong adoption of INTERCEPT and IFC products continues to fuel confidence in sustained growth.